IL161914A0 - Novel crystalline compound - Google Patents

Novel crystalline compound

Info

Publication number: IL161914A0
Authority: IL; Israel
Prior art keywords: crystalline compound; novel crystalline; novel; compound; crystalline
Prior art date: 2001-12-06

Application number

IL16191402A

Other languages

English (en)

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-06

Filing date

2002-11-25

Publication date

2005-11-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23326961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL161914(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-11-25 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-11-20 Publication of IL161914A0 publication Critical patent/IL161914A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hematology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL16191402A 2001-12-06 2002-11-25 Novel crystalline compound IL161914A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33898401P	2001-12-06	2001-12-06
PCT/IB2002/004948 WO2003048162A1 (en)	2001-12-06	2002-11-25	Novel crystalline compound

Publications (1)

Publication Number	Publication Date
IL161914A0 true IL161914A0 (en)	2005-11-20

Family

ID=23326961

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16191402A IL161914A0 (en)	2001-12-06	2002-11-25	Novel crystalline compound

Country Status (29)

Country	Link
US (2)	US6965027B2 (xx)
EP (1)	EP1451192B1 (xx)
JP (1)	JP4201135B2 (xx)
KR (1)	KR100691590B1 (xx)
CN (1)	CN1325498C (xx)
AR (1)	AR037635A1 (xx)
AT (1)	ATE497962T1 (xx)
AU (1)	AU2002348857B2 (xx)
BR (1)	BR0214761A (xx)
CA (1)	CA2469350C (xx)
CO (1)	CO5580780A2 (xx)
CY (1)	CY1111311T1 (xx)
DE (1)	DE60239146D1 (xx)
DK (1)	DK1451192T3 (xx)
ES (1)	ES2357942T3 (xx)
GT (1)	GT200200234A (xx)
HN (1)	HN2002000349A (xx)
IL (1)	IL161914A0 (xx)
MX (1)	MXPA04005401A (xx)
NO (1)	NO20042721L (xx)
NZ (1)	NZ532366A (xx)
PA (1)	PA8560201A1 (xx)
PE (1)	PE20030807A1 (xx)
PL (1)	PL221493B1 (xx)
RU (1)	RU2315052C2 (xx)
TW (1)	TW200300690A (xx)
UY (1)	UY27567A1 (xx)
WO (1)	WO2003048162A1 (xx)
ZA (1)	ZA200404270B (xx)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PA8474101A1 (es) *	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
MXPA02005675A (es)	1999-12-10	2002-09-02	Pfizer Prod Inc	Compuestos de pirrolo(2,3-d)pirimidina.
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
GT200200234A (es) *	2001-12-06	2003-06-27		Compuestos cristalinos novedosos
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
US7517886B2 (en)	2002-07-29	2009-04-14	Rigel Pharmaceuticals, Inc.	Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
MXPA05005576A (es) *	2002-11-26	2005-07-27	Pfizer Prod Inc	Procedimiento de tratamiento del rechazo a un trasplante.
EP1656372B1 (en)	2003-07-30	2013-04-10	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
BRPI0517887A (pt) *	2004-11-24	2008-10-21	Novartis Ag	combinações de inibidores de jaks
AR054416A1 (es)	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
CA2608367C (en)	2005-06-08	2014-08-19	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
JP5071374B2 (ja)	2005-07-14	2012-11-14	アステラス製薬株式会社	ヘテロ環ヤヌスキナーゼ３阻害剤
EP2251341A1 (en)	2005-07-14	2010-11-17	Astellas Pharma Inc.	Heterocyclic Janus kinase 3 inhibitors
US8232394B2 (en) *	2005-07-29	2012-07-31	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
US20070149506A1 (en)	2005-09-22	2007-06-28	Arvanitis Argyrios G	Azepine inhibitors of Janus kinases
US7598257B2 (en)	2005-12-13	2009-10-06	Incyte Corporation	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US8962643B2 (en)	2006-02-24	2015-02-24	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
GB0605691D0 (en) *	2006-03-21	2006-05-03	Novartis Ag	Organic Compounds
US8513270B2 (en)	2006-12-22	2013-08-20	Incyte Corporation	Substituted heterocycles as Janus kinase inhibitors
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
PT3070090T (pt)	2007-06-13	2019-03-20	Incyte Holdings Corp	Utilização de sais do inibidor da janus cinase (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo
RU2445098C2 (ru)	2007-07-11	2012-03-20	Пфайзер Инк.	Фармацевтические композиции и способы лечения сухих кератитов
JP2010535200A (ja) *	2007-07-30	2010-11-18	アストラゼネカ・アクチエボラーグ	２−ヒドロキシ−３−［５−（モルホリン−４−イルメチル）ピリジン−２−イル］−１ｈ−インドール−５−カルボニトリル・クエン酸塩の新しい結晶形態
DK2265607T3 (en)	2008-02-15	2017-03-13	Rigel Pharmaceuticals Inc	PYRIMIDIN-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES
UA101493C2 (ru)	2008-03-11	2013-04-10	Инсайт Корпорейшн	Производные азетидина и циклобутана как ингибиторы jak
US8138339B2 (en)	2008-04-16	2012-03-20	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
EA019973B1 (ru)	2008-04-16	2014-07-30	Портола Фармасьютиклз, Инк.	ИНГИБИТОРЫ Syk ПРОТЕИНКИНАЗ
EP2271631B1 (en)	2008-04-22	2018-07-04	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
ME01269B (me)	2008-08-20	2013-06-20	Zoetis Services Llc	Jedinjenja pirolo (2,3-d) pirimidina
US8385364B2 (en) *	2008-09-24	2013-02-26	Nec Laboratories America, Inc.	Distributed message-passing based resource allocation in wireless systems
US9145396B2 (en)	2008-12-01	2015-09-29	Targacept, Inc.	Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
US20100189791A1 (en)	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline malate formulation
CN102459270B (zh)	2009-04-20	2015-04-29	奥斯拜客斯制药有限公司	Janus激酶3的哌啶抑制剂
US8716303B2 (en)	2009-05-22	2014-05-06	Incyte Corporation	N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2761954C (en)	2009-05-22	2018-07-31	Incyte Corporation	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
WO2011028685A1 (en)	2009-09-01	2011-03-10	Incyte Corporation	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PT2486041E (pt)	2009-10-09	2013-11-14	Incyte Corp	Derivados hidroxilo, ceto e glucuronido de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentil-propanonitrilo
HRP20160326T1 (hr)	2010-03-10	2016-05-20	Incyte Holdings Corporation	Derivati piperidin-4-il azetidina kao inhibitori jak1
EA035981B1 (ru)	2010-05-21	2020-09-09	Инсайт Холдингс Корпорейшн	Композиция ингибитора jak для местного применения
WO2012061428A2 (en)	2010-11-01	2012-05-10	Portola Pharmaceuticals, Inc.	Nicotinamides as jak kinase modulators
JP5917544B2 (ja)	2010-11-19	2016-05-18	インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅＨｏｌｄｉｎｇｓＣｏｒｐｏｒａｔｉｏｎ	Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
JP5917545B2 (ja)	2010-11-19	2016-05-18	インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅＨｏｌｄｉｎｇｓＣｏｒｐｏｒａｔｉｏｎ	Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
EP2481411A1 (en) *	2011-01-27	2012-08-01	Ratiopharm GmbH	Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
EP2481397A1 (en)	2011-01-27	2012-08-01	Ratiopharm GmbH	Pharmaceutical compositions comprising tasocitinib
ES2547916T3 (es)	2011-02-18	2015-10-09	Novartis Pharma Ag	Terapia de combinación de inhibidores de mTOR/JAK
EP2691395B1 (en)	2011-03-28	2017-08-30	ratiopharm GmbH	Processes for preparing tofacitinib salts
RU2013144975A (ru)	2011-04-08	2015-05-20	Пфайзер Инк.	Кристаллические и некристаллические формы тофацитиниба и фармацевтическая композиция, содержащая тофацитиниб, и усилитель проникновения
BR112013032720A2 (pt)	2011-06-20	2016-09-13	Incyte Corp	"derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados"
CA2844507A1 (en)	2011-08-10	2013-02-14	Novartis Pharma Ag	Jak pi3k/mtor combination therapy
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
AU2012340555B2 (en)	2011-11-23	2016-10-20	Portola Pharmaceuticals, Inc.	Pyrazine kinase inhibitors
CN107898790B (zh)	2011-11-30	2024-06-21	埃默里大学	用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
EP3170827A1 (en)	2011-12-15	2017-05-24	ratiopharm GmbH	Tofacitinib mono-oxalate salt
WO2013173506A2 (en)	2012-05-16	2013-11-21	Rigel Pharmaceuticals, Inc.	Method of treating muscular degradation
TW201406761A (zh)	2012-05-18	2014-02-16	Incyte Corp	做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP2903970A4 (en)	2012-10-08	2016-11-30	Portola Pharm Inc	SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
SG10202111768XA (en)	2012-11-15	2021-11-29	Incyte Holdings Corp	Sustained-release dosage forms of ruxolitinib
US9481679B2 (en)	2012-12-17	2016-11-01	Sun Pharmaceutical Industries Limited	Process for the preparation of tofacitinib and intermediates thereof
EP2938616A4 (en) *	2012-12-28	2016-06-15	Glenmark Pharmaceuticals Ltd	PROCESSING METHOD FOR THE PRODUCTION OF TOFACITINIB AND INTERMEDIATE PRODUCTS THEREOF
CN103073552B (zh) *	2013-02-05	2015-08-12	华润赛科药业有限责任公司	一种无定型枸橼酸托法替尼的制备方法
HUE042466T2 (hu)	2013-03-06	2019-06-28	Incyte Holdings Corp	Eljárás és köztitermékek JAK inhibitor elõállítására
JP6041823B2 (ja)	2013-03-16	2016-12-14	ファイザー・インク	トファシチニブの経口持続放出剤形
WO2014174073A1 (en)	2013-04-26	2014-10-30	Sandoz Ag	Sustained release formulations of tofacitinib
US20160122354A1 (en) *	2013-06-05	2016-05-05	Srinivasan Thirumalai Rajan	PROCESS FOR THE PREPARATION OF (3R,4R)-4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL-AMINO)-ß-OXO-1-PIPERIDINEPROPANENITRILE AND ITS SALTS
CN104341422A (zh) *	2013-07-26	2015-02-11	重庆医药工业研究院有限责任公司	托菲替尼的中间体及其制备方法
PH12019502074B1 (en)	2013-08-07	2023-10-18	Incyte Holdings Corp	Sustained release dosage forms for a jak1 inhibitor
CN104447751A (zh) *	2013-09-16	2015-03-25	天津市汉康医药生物技术有限公司	一种托法替尼化合物
CN104447752A (zh) *	2013-09-16	2015-03-25	天津市汉康医药生物技术有限公司	一种托法替尼水合物及其制备方法
CN104292231B (zh) *	2013-09-17	2016-11-30	广东东阳光药业有限公司	一种枸橼酸托法替尼的制备方法
WO2015051738A1 (en) *	2013-10-08	2015-04-16	Sunshine Lake Pharma Co., Ltd.	Tofacitinib citrate
CN103585126A (zh) *	2013-11-18	2014-02-19	南京艾德凯腾生物医药有限责任公司	一种托法替尼组合物及制备方法
TR201904767T4 (tr) *	2013-12-09	2019-05-21	Unichem Lab Ltd	(3R,4R)-(1-benzil-4-metilpiperidin-3-il)-metilamin hazırlanması için geliştirilmiş bir işlem.
CN104774206A (zh) *	2014-01-14	2015-07-15	江苏柯菲平医药股份有限公司	制备枸橼酸托伐替尼晶型a的新方法
CA2881262A1 (en) *	2014-02-06	2015-08-06	Prabhudas Bodhuri	Solid forms of tofacitinib salts
WO2015184305A1 (en)	2014-05-30	2015-12-03	Incyte Corporation	TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
CN104387392B (zh) *	2014-08-22	2016-09-28	中孚药业股份有限公司	制备托法替布的方法
WO2017017542A1 (en) *	2015-07-27	2017-02-02	Unichem Laboratories Limited	Tofacitinib orally disintegrating tablets
CN105348287A (zh) *	2015-11-30	2016-02-24	宁波立华制药有限公司	一种枸橼酸托法替布的新型合成工艺
WO2017125417A1 (en)	2016-01-18	2017-07-27	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Tofacitinib as vaccination immune modulator
CA3033456C (en) *	2016-11-23	2021-03-09	Wuxi Fortune Pharmaceutical Co., Ltd	Crystal forms and salt forms of 7h-pyrrolo[2,3-d]pyrimidine compounds and preparation method thereof
WO2018172821A1 (en) *	2017-03-23	2018-09-27	Phalanx Labs Private Limited	Novel tofacitinib addition salts and process for the preparation thereof
CN106967072B (zh) *	2017-04-12	2019-05-03	山东裕欣药业有限公司	一种枸橼酸托法替布晶型化合物及其制备方法
CN109293682A (zh) *	2017-07-25	2019-02-01	重庆医药工业研究院有限责任公司	一种托法替布杂质及其制备方法
AR113922A1 (es)	2017-12-08	2020-07-01	Incyte Corp	Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
SG11202007164UA (en)	2018-01-30	2020-08-28	Incyte Corp	Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
WO2019182322A1 (ko) *	2018-03-20	2019-09-26	삼진제약주식회사	신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
CN108484607A (zh) *	2018-03-26	2018-09-04	山东科兴生物制品有限公司	枸橼酸托法替布的新型制备方法
WO2019191684A1 (en)	2018-03-30	2019-10-03	Incyte Corporation	Treatment of hidradenitis suppurativa using jak inhibitors
EP3787664B1 (en)	2018-05-03	2024-02-28	The United States of America, as represented by the Secretary, Department of Health and Human Services	Peptide hydrogels for delivery of immunosuppressive drugs and uses thereof
US20190381046A1 (en) *	2018-06-14	2019-12-19	Andrew HANNA	Tofacitinib and baclofen compositions and applications
CN109516991B (zh) *	2018-12-29	2020-08-07	山东罗欣药业集团股份有限公司	一种枸橼酸托法替尼晶型化合物及其制备方法
NL2022471B1 (en)	2019-01-29	2020-08-18	Vationpharma B V	Solid state forms of oclacitinib
WO2020172714A1 (en)	2019-02-27	2020-09-03	Samson Clinical Pty Ltd	Treatment of autoimmune disease
IL288024B1 (en)	2019-05-14	2025-08-01	Provention Bio Inc	Methods and compositions for preventing type
KR102209701B1 (ko)	2019-08-16	2021-01-29	유니셀랩 주식회사	토파시티닙의 신규한 결정형 형태 및 이의 제조방법
WO2021094953A1 (en)	2019-11-14	2021-05-20	Pfizer Inc.	1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
US20230149407A1 (en)	2020-04-04	2023-05-18	Pfizer Inc.	Methods of Treating Coronavirus Disease 2019
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
US12006366B2 (en)	2020-06-11	2024-06-11	Provention Bio, Inc.	Methods and compositions for preventing type 1 diabetes
EP4180042A1 (en)	2021-11-15	2023-05-17	Sanovel Ilac Sanayi Ve Ticaret A.S.	A film coated tablet comprising micronized tofacitinib

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6136595A (en) *	1993-07-29	2000-10-24	St. Jude Children's Research Hospital	Jak kinases and regulations of cytokine signal transduction
US5389509A (en) *	1993-10-04	1995-02-14	Eastman Kodak Company	Ultrathin high chloride tabular grain emulsions
DK0682027T3 (da) *	1994-05-03	1998-05-04	Ciba Geigy Ag	Pyrrolopyrimidinderivater med antiproliferativ virkning
PT831829E (pt) *	1995-06-07	2003-12-31	Pfizer	Derivados de pirimidina heterociclicos de aneis fundidos
CA2262421C (en) *	1996-08-23	2007-10-02	Novartis Ag	Substituted pyrrolopyrimidines and processes for their preparation
AU6568398A (en) *	1997-03-24	1998-10-20	Pharmacia & Upjohn Company	Method for identifying inhibitors of jak2/cytokine receptor binding
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
PL198640B1 (pl)	1998-06-19	2008-07-31	Pfizer Prod Inc	Związki pirolo[2,3-d]pirymidynowe, środek farmaceutyczny i zastosowanie tych związków
US6080747A (en) *	1999-03-05	2000-06-27	Hughes Institute	JAK-3 inhibitors for treating allergic disorders
MXPA02005675A (es) *	1999-12-10	2002-09-02	Pfizer Prod Inc	Compuestos de pirrolo(2,3-d)pirimidina.
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
GT200200234A (es) *	2001-12-06	2003-06-27		Compuestos cristalinos novedosos

2002
- 2002-11-21 GT GT200200234A patent/GT200200234A/es unknown
- 2002-11-25 JP JP2003549352A patent/JP4201135B2/ja not_active Expired - Lifetime
- 2002-11-25 CA CA002469350A patent/CA2469350C/en not_active Expired - Lifetime
- 2002-11-25 ES ES02781589T patent/ES2357942T3/es not_active Expired - Lifetime
- 2002-11-25 WO PCT/IB2002/004948 patent/WO2003048162A1/en not_active Ceased
- 2002-11-25 DK DK02781589.3T patent/DK1451192T3/da active
- 2002-11-25 MX MXPA04005401A patent/MXPA04005401A/es active IP Right Grant
- 2002-11-25 NZ NZ532366A patent/NZ532366A/en not_active IP Right Cessation
- 2002-11-25 KR KR1020047008581A patent/KR100691590B1/ko not_active Ceased
- 2002-11-25 BR BR0214761-0A patent/BR0214761A/pt not_active Application Discontinuation
- 2002-11-25 RU RU2004117088/04A patent/RU2315052C2/ru active Protection Beyond IP Right Term
- 2002-11-25 PL PL370297A patent/PL221493B1/pl unknown
- 2002-11-25 AT AT02781589T patent/ATE497962T1/de active
- 2002-11-25 IL IL16191402A patent/IL161914A0/xx active IP Right Grant
- 2002-11-25 AU AU2002348857A patent/AU2002348857B2/en active Active
- 2002-11-25 EP EP02781589A patent/EP1451192B1/en not_active Expired - Lifetime
- 2002-11-25 DE DE60239146T patent/DE60239146D1/de not_active Expired - Lifetime
- 2002-11-25 CN CNB028235878A patent/CN1325498C/zh not_active Expired - Lifetime
- 2002-12-02 TW TW091134957A patent/TW200300690A/zh unknown
- 2002-12-03 HN HN2002000349A patent/HN2002000349A/es unknown
- 2002-12-03 PE PE2002001162A patent/PE20030807A1/es not_active Application Discontinuation
- 2002-12-04 AR ARP020104686A patent/AR037635A1/es not_active Application Discontinuation
- 2002-12-04 US US10/310,078 patent/US6965027B2/en not_active Expired - Lifetime
- 2002-12-05 UY UY27567A patent/UY27567A1/es not_active Application Discontinuation
- 2002-12-06 PA PA20028560201A patent/PA8560201A1/es unknown
2004
- 2004-05-20 CO CO04046635A patent/CO5580780A2/es not_active Application Discontinuation
- 2004-05-31 ZA ZA2004/04270A patent/ZA200404270B/en unknown
- 2004-06-28 NO NO20042721A patent/NO20042721L/no not_active Application Discontinuation
2005
- 2005-01-10 US US11/032,990 patent/US7803805B2/en not_active Expired - Fee Related
2011
- 2011-03-04 CY CY20111100256T patent/CY1111311T1/el unknown

Also Published As

Publication number	Publication date
PA8560201A1 (es)	2003-12-10
KR100691590B1 (ko)	2007-03-09
KR20050044691A (ko)	2005-05-12
RU2315052C2 (ru)	2008-01-20
HK1070653A1 (zh)	2005-06-24
CN1325498C (zh)	2007-07-11
US7803805B2 (en)	2010-09-28
PL221493B1 (pl)	2016-04-29
CO5580780A2 (es)	2005-11-30
ATE497962T1 (de)	2011-02-15
JP4201135B2 (ja)	2008-12-24
CA2469350A1 (en)	2003-06-12
EP1451192A1 (en)	2004-09-01
AU2002348857A1 (en)	2003-06-17
JP2005511696A (ja)	2005-04-28
TW200300690A (en)	2003-06-16
ES2357942T3 (es)	2011-05-04
CY1111311T1 (el)	2015-08-05
US6965027B2 (en)	2005-11-15
AU2002348857B2 (en)	2008-12-04
WO2003048162A1 (en)	2003-06-12
PL370297A1 (en)	2005-05-16
MXPA04005401A (es)	2004-10-11
BR0214761A (pt)	2004-11-09
GT200200234A (es)	2003-06-27
RU2004117088A (ru)	2005-03-27
US20030130292A1 (en)	2003-07-10
US20050159434A1 (en)	2005-07-21
DE60239146D1 (de)	2011-03-24
DK1451192T3 (da)	2011-04-04
HN2002000349A (es)	2003-08-20
NZ532366A (en)	2006-11-30
CN1596257A (zh)	2005-03-16
NO20042721L (no)	2004-06-28
CA2469350C (en)	2009-09-29
PE20030807A1 (es)	2003-09-22
ZA200404270B (en)	2005-10-26
UY27567A1 (es)	2003-07-31
AR037635A1 (es)	2004-11-17
EP1451192B1 (en)	2011-02-09

Publication	Publication Date	Title
IL161914A0 (en)	2005-11-20	Novel crystalline compound
GB0119467D0 (en)	2001-10-03	Novel compound
GB0105895D0 (en)	2001-04-25	Novel compounds
GB0111861D0 (en)	2001-07-04	Novel compounds
GB0114719D0 (en)	2001-08-08	Compound
GB0118517D0 (en)	2001-09-19	Compound
GB0109103D0 (en)	2001-05-30	Novel compounds
GB0119793D0 (en)	2001-10-03	Novel compounds
GB0129121D0 (en)	2002-01-23	Compound
GB0127923D0 (en)	2002-01-16	Compound
GB0126849D0 (en)	2002-01-02	Novel compounds
GB0108226D0 (en)	2001-05-23	Novel crystalline forms
GB0103866D0 (en)	2001-04-04	Novel compounds
GB0107528D0 (en)	2001-05-16	Novel compound
GB0118159D0 (en)	2001-09-19	Compound
GB0125073D0 (en)	2001-12-12	Compound
GB0127800D0 (en)	2002-01-09	Compound
GB0117797D0 (en)	2001-09-12	Compound
GB0100644D0 (en)	2001-02-21	Compound
GB0114538D0 (en)	2001-08-08	Compound
GB0129847D0 (en)	2002-01-30	Novel compounds
GB0130505D0 (en)	2002-02-06	Novel compounds
GB0102570D0 (en)	2001-03-21	Novel Compounds
GB0130190D0 (en)	2002-02-06	Novel compounds
GB0127932D0 (en)	2002-01-16	Novel compounds

Legal Events

Date	Code	Title
2012-12-31	FF	Patent granted
2013-02-03	KB	Patent renewed
2016-11-30	KB	Patent renewed
2020-11-30	KB	Patent renewed